Cigna Q2 2026: revenue up 7% to $71.7B, full-year outlook nudged to $30.45
Cigna's second quarter reads close to neutral: revenue rose 7.0% to $71.67 billion and adjusted earnings per share of $7.78 landed just under the $7.826 consensus, while management lifted full-year guidance by only $0.10 to at least $30.45 per share. The soft spot is margin mix, where pharmacy benefit profit fell 27.0% and Cigna Healthcare carried the quarter.
1 · Expected vs. Actual
Free preview belowGAAP earnings per share were $6.29, up from $5.71, and adjusted earnings per share were $7.78, up from $7.20. Against the $7.826 consensus, adjusted EPS fell short by roughly $0.05, or 0.6%. Net income of $1.66 billion was 8.4% higher than $1.53 billion, so growth is real but there was no beat.
Revenue of $71.67 billion rose 7.0% from $67.18 billion a year earlier, with growth credited to both Evernorth Health Services and Cigna Healthcare. Gross margin was 20.9%, essentially flat versus 20.7% in the prior-year quarter. The bulk of the top line sits in Evernorth: Pharmacy Benefit Services generated $34.50 billion and Specialty and Care Services $26.97 billion, together dwarfing Cigna Healthcare's $11.73 billion.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.